v3.26.1
Business Combination (Details Textual)
₨ in Millions, £ in Millions, $ in Millions
 12 Months Ended
Aug. 01, 2024
INR (₨)
Jun. 26, 2024
INR (₨)
Mar. 31, 2026
INR (₨)
Mar. 31, 2026
USD ($)
Mar. 31, 2025
INR (₨)
Mar. 31, 2024
INR (₨)
Mar. 31, 2026
USD ($)
Mar. 31, 2026
GBP (£)
Mar. 31, 2025
GBP (£)
Jun. 26, 2024
GBP (£)
Disclosure of detailed information about business combination [line items]                    
Payment to acquire license ₨ 2,231                  
Percentage of royalty payables 4.50%                  
Revenues     ₨ 335,933 [1] $ 3,580 ₨ 325,535 [1] ₨ 279,164 [1]        
Consideration transferred, acquisition-date fair value     220   2,916          
Profit before tax     54,817 $ 584 76,784 ₨ 71,870        
Goodwill     12,893   11,810   $ 137      
Nestle India [Member]                    
Disclosure of detailed information about business combination [line items]                    
Subscription contributed ₨ 7,056                  
Proportion of ownership interest in subsidiary 49.00%                  
Goodwill ₨ 207                  
Other intangible assets 1,982                  
Property, plant and equipment ₨ 42                  
Nestle India [Member] | Nutraceuticals Subsidiary [Member]                    
Disclosure of detailed information about business combination [line items]                    
Proportion of ownership interest in subsidiary 49.00%                  
Non-controlling interest in acquiree recognised at acquisition date     3,394   3,778          
Dr. Reddys Laboratories [Member]                    
Disclosure of detailed information about business combination [line items]                    
Subscription contributed ₨ 7,344                  
Dr. Reddys Laboratories [Member] | Nutraceuticals Subsidiary [Member]                    
Disclosure of detailed information about business combination [line items]                    
Proportion of ownership interest in subsidiary 51.00%                  
Haleon [Member]                    
Disclosure of detailed information about business combination [line items]                    
Consideration transferred, acquisition-date fair value   ₨ 56,121 53,660             £ 500
Cash transferred   51,407               458
Consideration payable   ₨ 4,714               42
Goodwill     7,170              
Other intangible assets     54,973              
Deferred tax liabilities     8,483              
Haleon [Member] | Transitional Distribution Services Agreement [Member]                    
Disclosure of detailed information about business combination [line items]                    
Revenues         12,020          
Profit before tax         1,011          
Haleon [Member] | Northstar Switzerland Sarl [Member]                    
Disclosure of detailed information about business combination [line items]                    
Proportion of ownership interest in subsidiary   100.00%                
Cash transferred   ₨ 51,407               458
Contingent consideration recognised as of acquisition date   4,714               42
Haleon [Member] | Northstar Switzerland Sarl [Member] | NRT [Member]                    
Disclosure of detailed information about business combination [line items]                    
Consideration payable     ₨ 3,389   ₨ 1,655     £ 27 £ 15  
Haleon [Member] | Northstar Switzerland Sarl [Member] | Sales Target 2024 [Member]                    
Disclosure of detailed information about business combination [line items]                    
Consideration transferred, acquisition-date fair value   ₨ 56,121               £ 500
[1] Revenues for the year ended March 31, 2026 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, of Rs.7,270 (as compared to Rs.9,389 and Rs.10,707 for the years ended March 31, 2025 and 2024, respectively) and from the PSAI segment to the Others segment of Rs.0 (as compared to Rs.0 and Rs.72 for the years ended March 31, 2025 and 2024, respectively)